Amy L. Hartman, PhD
Research Manager, RBL|
Research Assistant Professor
Infectious Disease & Microbiology
3501 Fifth Avenue
Pittsburgh, Pennsylvania 15261
Phone: (412) 648-8765
Fax: (412) 648-8917
Phone: (412) 648-1922
Bethel, Laura M
Caroline, Amy L
Hartman, Amy Lynn
Powell, Diana Sue
Dr. Hartman received her bachelor's degree in Biology from Washington and Jefferson College in 1998. She received her Ph.D. in Molecular Virology from the Department of Molecular Genetics and Biochemistry at the University of Pittsburgh School of Medicine in 2003. Her graduate thesis was done in the laboratory of Mickey Murphey-Corb, Ph.D. and focused on host factors controlling Simian Immunodeficiency Virus (SIV) infection in rhesus macaques.
Amy then did a post-doctoral fellowship in the Special Pathogens Branch at the Centers for Disease Control and Prevention in Atlanta, GA under Stuart Nichol, Ph.D. Her work focused on viral virulence factors contributing to severe disease induced by infection with Ebola Zaire virus.
Amy returned to the University of Pittsburgh in 2007 as the Research Manager of the Regional Biocontainment Laboratory as well as Research Instructor in the Department of Infectious Disease and Microbiology in the Graduate School of Public Health.
Dr. Hartman's research currently focuses on development of animal models for Rift Valley Fever virus (RVFV) after aerosol infection. With funding from the Department of Defense, the goal is to develop animal models that mimic the different disease outcomes seen in humans after RVFV infection. Well-defined disease models will be useful for testing potential vaccines and therapeutics that can be used to protect the US military and civilian populations.
- Bales, J.M., D.S. Powell, L.M. Bethel, D.S. Reed, and A.L. Hartman. Choice of inbred rat strain impacts lethality and disease course after respiratory infection with Rift Valley Fever Virus. 2012. Frontiers in Cellular Infection Microbiology. 2(105):1-14.
- Hartman, A.L., K.S. Cole, and L.C. Homer. Verification of Inactivation Methods for Removal of Biological Materials from a Biosafety Level-3 Select Agent Facility. 2012. Applied Biosafety: Journal of the American Biological Safety Association. 17(2):70-75.
Homer, L.C., A.L. Hartman, D.T. Heflin, A.M. Trichel, D.S. Reed, and K.S. Cole. 2011. Enhancement of the Mentored Training Program for Investigative Staff at the University of Pittsburgh Regional Biocontainment Laboratory. Applied Biosafety: Journal of the American Biological Safety Association. 16(4):231-239.
- Ross TM, Bhardwaj N, Bissel SJ, Hartman AL, Smith DR. Animal models of Rift Valley fever virus infection. Virus Res. 2011 Nov 4. [Epub ahead of print.PMID:22086058
- Hartman, A.L., L.C. Homer, A.M. Trichel, D. Fisher, J. Frerotte, and K.S. Cole. 2010. Evolution of a Facility-Specific BSL-3 Training Program for the University of Pittsburgh Regional Biocontainment Laboratory. Applied Biosafety: Journal of the American Biological Safety Association. 15(3):137-141.
- Bird BH, Githinji JW, Macharia JM, Kasiiti JL, Muriithi RM, Gacheru SG, Musaa JO, Towner JS, Reeder SA, Oliver JB, Stevens TL, Erickson BR, Morgan LT, Khristova ML, Hartman AL, Comer JA, Rollin PE, Ksiazek TG, Nichol ST. Multiple virus lineages sharing recent common ancestry were associated with a Large Rift Valley fever outbreak among livestock in Kenya during 2006-2007. J Virol. 2008 Nov;82(22):11152-66. Epub 2008 Sep 10. PMID:18786992
- Hartman AL, Ling L, Nichol ST, Hibberd ML. Whole-genome expression profiling reveals that inhibition of host innate immune response pathways by Ebola virus can be reversed by a single amino acid change in the VP35 protein. J Virol. 2008 Jun;82(11):5348-58. Epub 2008 Mar 19. PMID:18353943
- Hartman AL, Bird BH, Towner JS, Antoniadou ZA, Zaki SR, Nichol ST. Inhibition of IRF-3 activation by VP35 is critical for the high level of virulence of ebola virus. J Virol. 2008 Mar;82(6):2699-704. Epub 2008 Jan 16. PMID:18199658
- Bird BH, Albariño CG, Hartman AL, Erickson BR, Ksiazek TG, Nichol ST. Rift valley fever virus lacking the NSs and NSm genes is highly attenuated, confers protective immunity from virulent virus challenge, and allows for differential identification of infected and vaccinated animals. J Virol. 2008 Mar;82(6):2681-91. Epub 2008 Jan 16. PMID:18199647
- Hartman AL, Dover JE, Towner JS, Nichol ST. Reverse genetic generation of recombinant Zaire Ebola viruses containing disrupted IRF-3 inhibitory domains results in attenuated virus growth in vitro and higher levels of IRF-3 activation without inhibiting viral transcription or replication.
J Virol. 2006 Jul;80(13):6430-40. PMID:16775331